肿瘤免疫：生物创新【研报】

pengxuleo

7 x7 x7 O* T' f' [3 H/ M3 B

( R. {" C- J3 v( n7 K- y8 B目录# k7 n) l* v3 F( N
免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4
% O  Z, V' ]. v抗癌领域新突破 .................................................................................................................. 4* }1 M: D* c+ x& s
600 亿美元市场空间 ............................................................................................................ 4+ z5 `" d' F# `4 v/ t
免疫检查点的突破——PD-1 ....................................................................................................... 5
! X0 X! e, @) Q# u5 a' nPD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 51 e+ b, w/ I7 a
PD-1 重磅产品频出 ............................................................................................................. 5- l; j- J' O8 @+ Y- c' `
在研PD-1 单抗全面开花 ....................................................................................................... 6: A% E/ x1 ^% }: U% ]4 I" R
PD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 7
; Z& z; M! [6 z1 c) E: @/ O  BPD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
1 E9 ^( K3 G% c& p( ^' CPD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 9# X8 }+ z! v" F
PD-1 市场前景广阔 ........................................................................................................... 10
6 o2 A6 X. R* r. ?免疫治疗热门靶点——PD-L1 ................................................................................................... 19
% x! ^# o+ Y4 ?; PPD-L1 单抗免疫疗法原理 .................................................................................................... 193 S& E8 P' A) ]
PD-L1 单抗在研情况 .......................................................................................................... 197 v8 U' c6 y4 l9 Y
PD-L1 联用——多靶点治疗新选择 ......................................................................................... 19$ U0 j* I$ d) P2 ~8 {1 {
PD-L1 未来市场 ............................................................................................................... 20: V4 G8 {# s; b' {
免疫治疗另一靶点——CTLA-4 .................................................................................................. 216 Y. I5 K8 _& v# c4 f0 F7 c
CTLA-4 单抗免疫疗法原理 ................................................................................................... 21! X8 z! i" S1 w8 \' e9 G
CTLA-4 单抗已上市产品 ..................................................................................................... 21
1 m# l$ z3 Q4 bCTLA-4 在研产品.............................................................................................................. 22
+ }; H1 r* p( c' ?. LCTLA-4 的未来，联合用药是出路 .......................................................................................... 23
; I3 c( P7 k3 T/ v8 m5 ~) t相关公司简介 ........................................................................................................................ 24
' f" W2 [2 R( J/ K# M  H0 c3 {* ~5 t君实生物 ........................................................................................................................ 24
$ j6 }/ K% L8 e) q" i恒瑞医药（确信买入评级） .................................................................................................. 25
6 f9 L  i- K3 S7 t1 K4 l百时美施贵宝（BMS） ....................................................................................................... 26
0 w& N: Q2 H- Q. f+ R: ?: r4 j4 Q8 ]' ?% _默克（Merck） ................................................................................................................ 27
9 t% Z) U3 z0 D1 s! i% B
9 h. i1 P+ G( @
% _# |. q# s6 F5 r% C$ }[hide][/hide]

cantonchn

saberche

好好学习一下

chimo100

谢谢

xiaoheilong

感谢分享！

18351507829

本本9705

xx

FreeCell

看看

yinfuhua

学习。

kblb1983

谢谢分享